Minocycline, an antibiotic approved to treat various infections including acne, can increase vocalizations and provide long-lasting improvements in anxiety in a fragile X mouse model, according to two posters presented at the Society for Neuroscience annual meeting in San Diego.
Contrary to popular belief, receptors both outside and inside a cell regulate a cellular pathway that is overactive in people with fragile X syndrome, researchers reported Tuesday at the Society for Neuroscience annual meeting in San Diego. The finding could have significant implications for drug treatments of fragile X syndrome.
A study of mice with tuberous sclerosis — a single-gene disorder that is related to autism — suggests that most forms of autism share a common feature: an imbalance of proteins at the synapse, the junction between neurons. The work was presented Monday at the Society for Neuroscience annual meeting in San Diego.
Seaside Therapeutics has announced results from a phase II clinical trial showing that, in children with autism, STX209 lowers agitation, tantrums, irritability and social withdrawal.
The amygdala, a brain region that regulates fear and anxiety, shows abnormal neuronal signaling in a mouse model of fragile X syndrome, according to two studies published this summer. These are the first to explore cellular defects in the region in fragile X.
Mouse models of fragile X syndrome show defects in two kinds of potassium channels — ubiquitous pores that control the flow of electrical current across neurons — in a brain area that processes sound, according to two papers published this summer.
Scientists have for the first time captured a dynamic picture of brain defects in young mouse models of fragile X syndrome. The findings appeared in June in the Journal of Neuroscience.
A decade of research on the biology of autism, combined with a steady rise in diagnoses, has finally piqued the pharmaceutical industry’s interest in developing drugs for the disorder. Preliminary data from one small clinical trial already show positive results, and results from several others are expected early this summer.
New pharmacological and behavioral interventions can reverse characteristics of autism in a mouse model of the disorder, according to unpublished results presented in poster sessions today at the Society for Neuroscience meeting.
Research on mouse models published in the past year is paving the way to reversing the symptoms of some autism-related disorders, National Institute Health directors told a packed room of 80 reporters at the morning at the Society for Neuroscience conference.